JP7730765B2 - Ｍａｇｅ－ａ４ ｔ細胞受容体およびその使用方法 - Google Patents

Ｍａｇｅ－ａ４ ｔ細胞受容体およびその使用方法

Info

Publication number
JP7730765B2
JP7730765B2 JP2021575366A JP2021575366A JP7730765B2 JP 7730765 B2 JP7730765 B2 JP 7730765B2 JP 2021575366 A JP2021575366 A JP 2021575366A JP 2021575366 A JP2021575366 A JP 2021575366A JP 7730765 B2 JP7730765 B2 JP 7730765B2
Authority
JP
Japan
Prior art keywords
tcr
chain variable
variable domain
mage
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021575366A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022537359A (ja
JP2022537359A5 (https=
Inventor
ナタリー バウワーマン，
ケイガン ギュラー，
ジョアンナ ハンセン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2022537359A publication Critical patent/JP2022537359A/ja
Publication of JP2022537359A5 publication Critical patent/JP2022537359A5/ja
Priority to JP2024135124A priority Critical patent/JP2024164066A/ja
Priority to JP2025135733A priority patent/JP2025166209A/ja
Application granted granted Critical
Publication of JP7730765B2 publication Critical patent/JP7730765B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4269—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
JP2021575366A 2019-06-18 2020-06-17 Ｍａｇｅ－ａ４ ｔ細胞受容体およびその使用方法 Active JP7730765B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024135124A JP2024164066A (ja) 2019-06-18 2024-08-13 Ｍａｇｅ－ａ４ ｔ細胞受容体およびその使用方法
JP2025135733A JP2025166209A (ja) 2019-06-18 2025-08-18 Ｍａｇｅ－ａ４ ｔ細胞受容体およびその使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962862726P 2019-06-18 2019-06-18
US62/862,726 2019-06-18
US201962871793P 2019-07-09 2019-07-09
US62/871,793 2019-07-09
PCT/US2020/038142 WO2020257288A2 (en) 2019-06-18 2020-06-17 Mage-a4 t cell receptors and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024135124A Division JP2024164066A (ja) 2019-06-18 2024-08-13 Ｍａｇｅ－ａ４ ｔ細胞受容体およびその使用方法

Publications (3)

Publication Number Publication Date
JP2022537359A JP2022537359A (ja) 2022-08-25
JP2022537359A5 JP2022537359A5 (https=) 2023-06-23
JP7730765B2 true JP7730765B2 (ja) 2025-08-28

Family

ID=74040867

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2021575366A Active JP7730765B2 (ja) 2019-06-18 2020-06-17 Ｍａｇｅ－ａ４ ｔ細胞受容体およびその使用方法
JP2024135124A Pending JP2024164066A (ja) 2019-06-18 2024-08-13 Ｍａｇｅ－ａ４ ｔ細胞受容体およびその使用方法
JP2025135733A Pending JP2025166209A (ja) 2019-06-18 2025-08-18 Ｍａｇｅ－ａ４ ｔ細胞受容体およびその使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024135124A Pending JP2024164066A (ja) 2019-06-18 2024-08-13 Ｍａｇｅ－ａ４ ｔ細胞受容体およびその使用方法
JP2025135733A Pending JP2025166209A (ja) 2019-06-18 2025-08-18 Ｍａｇｅ－ａ４ ｔ細胞受容体およびその使用方法

Country Status (15)

Country Link
US (1) US20220324939A1 (https=)
EP (1) EP3986938A4 (https=)
JP (3) JP7730765B2 (https=)
KR (1) KR20220035387A (https=)
CN (2) CN118994364A (https=)
AU (1) AU2020295401A1 (https=)
BR (1) BR112021025548A2 (https=)
CA (1) CA3144253A1 (https=)
CL (2) CL2021003366A1 (https=)
CO (1) CO2022000281A2 (https=)
IL (1) IL289042A (https=)
MA (1) MA56548A (https=)
MX (1) MX2021015946A (https=)
PH (1) PH12021553152A1 (https=)
WO (1) WO2020257288A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
SG11201901634UA (en) * 2016-09-23 2019-04-29 Lion Tcr Pte Ltd An hbv antigen specific binding molecules and fragments thereof
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
PH12021553152A1 (en) * 2019-06-18 2022-08-15 Regeneron Pharma Mage-a4 t cell receptors and methods of use thereof
CN113621070A (zh) 2020-05-06 2021-11-09 华夏英泰（北京）生物技术有限公司 一种t细胞抗原受体、其多聚体复合物及其制备方法和应用
TW202229327A (zh) * 2020-10-02 2022-08-01 美國衛生與公眾服務部 針對含有g13d突變之ras之hla第ii類限制性dq t細胞受體
US12435444B2 (en) 2021-03-09 2025-10-07 Cdr-Life Ag Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same
MX2023010541A (es) 2021-03-09 2023-11-24 Cdr Life Ag Proteinas de union al antigeno del peptido del mhc mage-a4.
EP4422651A4 (en) * 2021-10-25 2025-12-17 Univ Texas PEPTIDES AND MANIPULATED T-CELL RECEPTORS FOR TARGETTING THE MAGE-A4 ANTIGEN AND METHOD FOR USE
EP4472742A1 (en) * 2022-02-03 2024-12-11 University College Cardiff Consultants Limited Novel t-cell receptor
WO2023238125A1 (en) * 2022-06-08 2023-12-14 Sheba Impact Ltd. Virus-specific recombinant t cell receptors and t cells comprising them
JP2025525382A (ja) * 2022-06-24 2025-08-05 アムジエン・インコーポレーテツド Ｍａｇｅａ４特異的ｔ細胞受容体
CA3264474A1 (en) 2022-09-14 2024-03-21 Cdr-Life Ag MAGE-A4 DOUBLE T LYMPHOCYTE ENGAGEMENT
JP2026509947A (ja) 2022-10-31 2026-03-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 養子細胞療法および標的化免疫サイトカインの組合せを用いてがんを処置する方法
EP4393942A1 (en) * 2022-12-29 2024-07-03 Keshihua (Nanjing) Biotechnology Co., Ltd Tcr, polypeptide, expression vector, host cell, pharmaceutical composition and method for obtaining tcr
AU2024214482A1 (en) 2023-02-03 2025-08-07 Zelluna Immunotherapy As Anti-mage-a4 t cell receptors
CN119569851A (zh) * 2023-09-05 2025-03-07 香雪生命科学技术（广东）有限公司 针对magea4的高亲和力tcr
WO2025233432A1 (en) * 2024-05-07 2025-11-13 Immatics Biotechnologies Gmbh Use and dosage of an antigen-binding protein comprising a tcr specific for an hla-a*02 restricted peptide

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019511222A (ja) 2016-03-16 2019-04-25 イマティクス バイオテクノロジーズ ゲーエムベーハー がんに対する免疫療法で使用するための形質移入ｔ細胞およびｔ細胞受容体
WO2020243134A1 (en) 2019-05-27 2020-12-03 Immatics US, Inc. Viral vectors and their use in adoptive cellular therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7311914B2 (en) * 2002-08-13 2007-12-25 Ludwig Institute For Cancer Research MAGE-A4 antigenic peptides and uses thereof
NL2014935B1 (en) * 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
SMT202200306T1 (it) * 2016-04-08 2022-09-14 Immunocore Ltd Recettori di cellule t
BR112018070637A2 (pt) * 2016-04-08 2019-02-05 Adaptimmune Ltd receptores de células t
DK3440106T3 (da) * 2016-04-08 2021-10-04 Adaptimmune Ltd T-cellereceptorer
PH12021553152A1 (en) * 2019-06-18 2022-08-15 Regeneron Pharma Mage-a4 t cell receptors and methods of use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019511222A (ja) 2016-03-16 2019-04-25 イマティクス バイオテクノロジーズ ゲーエムベーハー がんに対する免疫療法で使用するための形質移入ｔ細胞およびｔ細胞受容体
WO2020243134A1 (en) 2019-05-27 2020-12-03 Immatics US, Inc. Viral vectors and their use in adoptive cellular therapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JIA, Z. C. et al，Identification of Two Novel HLA-A*0201-Restricted CTL Epitopes Derived MAGE-A4，Clinical and Developmental Immunology，2010年，Article ID 567594
WU, Z. Y. et al，Identification of a Novel CD8+ T Cell Epitope Derived from Cancer-Testis Antigen MAGE-4 in Oesophageal Carcinoma，Scandinavian Journal of Immunology，2011年，Vol.74，pp.561-567

Also Published As

Publication number Publication date
PH12021553152A1 (en) 2022-08-15
JP2024164066A (ja) 2024-11-26
KR20220035387A (ko) 2022-03-22
CN118994364A (zh) 2024-11-22
JP2022537359A (ja) 2022-08-25
CN114585646A (zh) 2022-06-03
WO2020257288A2 (en) 2020-12-24
BR112021025548A2 (pt) 2022-05-17
CA3144253A1 (en) 2020-12-24
US20220324939A1 (en) 2022-10-13
CN114585646B (zh) 2024-09-03
CL2021003366A1 (es) 2022-08-19
IL289042A (en) 2022-02-01
EP3986938A2 (en) 2022-04-27
MA56548A (fr) 2022-04-27
JP2025166209A (ja) 2025-11-05
AU2020295401A1 (en) 2022-02-10
WO2020257288A3 (en) 2021-04-08
EP3986938A4 (en) 2023-06-28
CO2022000281A2 (es) 2022-01-28
CL2024000119A1 (es) 2024-05-31
MX2021015946A (es) 2022-04-18

Similar Documents

Publication Publication Date Title
JP7730765B2 (ja) Ｍａｇｅ－ａ４ ｔ細胞受容体およびその使用方法
JP7569313B2 (ja) Ｎｙ－ｅｓｏ－１ ｔ細胞受容体およびそれらの使用の方法
JP7394840B2 (ja) 複数のｈｌａ－ｇアイソフォームに対するキメラ抗原レセプター
JP2025092600A (ja) 黒色腫において優先的に発現する抗原（ｐｒａｍｅ）ｔ細胞受容体およびそれらの使用方法
US20220281994A1 (en) Chimeric Antigen Receptors with MAGE-A4 Specificity and Uses Thereof
JP2023534808A (ja) 養子細胞療法のための標的共刺激を提供する受容体
JP2023133505A (ja) サイクリンａ１特異的ｔ細胞受容体およびその使用
KR20260016919A (ko) 제시된 hpv16-, mart1-, cmv-, ebv-, 또는 인플루엔자-펩티드에 결합하는 t 세포 수용체
EA048220B1 (ru) Т-клеточные рецепторы к предпочтительно экспрессируемому антигену меланомы (prame) и способы их применения
EA048440B1 (ru) T-клеточные рецепторы к mage-a4 и способы их применения
EA048202B1 (ru) T-клеточные рецепторы ny-eso-1 и способы их применения
WO2026075949A1 (en) Death receptor 5-targeted chimeric antigen receptors and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230615

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230615

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240813

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241022

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250122

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250612

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250730

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250818

R150 Certificate of patent or registration of utility model

Ref document number: 7730765

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150